Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Dasatinib, a dual Src family kinase and Abl inhibitor, is being tested clinically for the treatment of prostate cancer bone metastasis. Bidirectional interactions between osteoblasts and prostate cancer cells are critical in the progression of prostate cancer in bone, but the effect of dasatinib on osteoblasts is unknown. We found that dasatinib inhibited proliferation of primary mouse osteoblasts isolated from mouse calvaria and the immortalized MC3T3-E1 cell line. In calvarial osteoblasts from Col-luc transgenic mice carrying osteoblast-specific Col1α1 promoter reporter, luciferase activity was inhibited. Dasatinib also inhibited fibroblast growth factor-2-induced osteoblast proliferation, but strongly promoted osteoblast differentiation, as reflected by stimulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization. To determine how dasatinib blocks proliferative signaling in osteoblasts, we analyzed the expression of a panel of tyrosine kinases, including Src, Lyn, Fyn, Yes and Abl, in osteoblasts. In the Src family kinases, only Src was activated at a high level. Abl was expressed at a low level in osteoblasts. Phosphorylation of Src-Y419 or Abl-Y245 was inhibited by dasatinib treatment. Knockdown of either Src or Abl by lenti-shRNA in osteoblasts enhances osteoblast differentiation, suggesting that dasatinib enhances osteoblast differentiation through inhibition of both Src and Abl.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Src family kinases in tumor progression and metastasis
Summy, J. M., & Gallick, G. E. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023772912750 · Cited by 827 · cited 1×
“The Src family protein tyrosine kinases are involved in several cancer types, including colorectal (Cartwright et al., 1989, 1990; Talamonti et al., 1993) and pancreatic (Ito et al., 2003; Summy and Gallick, 2003; Trevino et al., 2006) cancers.”
Self-citationIncrease in activity and level of pp60c-src in progressive stages of human colorectal cancer.
Talamonti, M. S., Roh, M. S., Curley, S. A., & Gallick, G. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116200 · Cited by 399
Self-citationActivation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.
Cartwright, C. A., Meisler, A. I., & Eckhart, W. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.2.558 · Cited by 277 · cited 2×
“The Src family protein tyrosine kinases are involved in several cancer types, including colorectal (Cartwright et al., 1989; Cartwright et al., 1990; Talamonti et al., 1993) and pancreatic (Ito et al.”
pp60c-src activation in human colon carcinoma.
Cartwright, C. A., Kamps, M. P., Meisler, A. I., Pipas, J. M., & Eckhart, W. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114113 · Cited by 265
Src continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111 · cited 1×
“Owing to its effectiveness in halting prostate cancer cell proliferation and invasion, dasatinib is being tested as an inhibitor of progression of prostate cancer bone metastasis in clinical trials (Kopetz et al., 2007; Araujo and Logothetis, 2009).”
Self-citation
Cited by
Montero, J. C., Seoane, S., Ocaña, A., & Pandiella, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2616 · Cited by 298
“On one hand, dasatinib induces osteoblast differentiation from bone marrow–derived mesenchymal stromal cells, therefore increasing bone formation (18, 19).”
Bone metastasis in prostate cancer: emerging therapeutic strategies
Sturge, J., Caley, M. P., & Waxman, J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.67 · Cited by 256
Jun, J. H., Kim, J. Y., Choi, J. H., Lim, J.-Y., Kim, K., & Kim, G. J. (2020) · Stem Cells International · doi:10.1155/2020/5485738 · Cited by 33
Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair
Wang, M., Park, S., Nam, Y., Nielsen, J., Low, S. A., Srinivasarao, M., & Low, P. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00660 · Cited by 24
Metadata
- Authors
- Lee, Y.-C., Huang, C.-F., Murshed, M., Chu, K., Araujo, J. C., Ye, X., deCrombrugghe, B., Yu-Lee, L.-Y., Gallick, G. E., & Lin, S.-H.
- Venue
- Oncogene
- Published
- 2010-03-15
- Volume
- 29
- Issue
- 22
- Pages
- 3196-3207
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2161143036
- Cited by
- 79
- References
- 5
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.